About this trial
Nivolumab is is an immune checkpoint inhibitor and a type of monoclonal antibody that treats certain cancers by blocking PD-L1, a protein that prevents immune cells from attacking cancer cells. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found on certain cells in the body. Nivolumab prevents PD-1 from switching off these immune cells. This increases the ability of the immune system to kill tumour cells. Nivolumab is sold under the name Opdivo.
Relatlimab is a monoclonal antibody which blocks a specific immune checkpoint called Lymphocyte-Activation Gene-3 (LAG-3) on T Cells (T cell is a type of White Blood Cell that is part of the immune system). By blocking the LAG-3 pathway relatlimab reduces the immunosuppresive effects that cancer cells often use to evade the immune system. Blocking LAG-3 also helps to increase T cell activity which imporves the body’s ability to fight and eliminate tumour cells. It is currently sold under the brand name Opdualag for the treatment of melanoma.
The purpose of this study is to compare the efficacy of Nivolumab and Relatilmad Plus Chemo to Pembrolizumab Plus Chemo in the treatment of patients with Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (Pembrolizumab is a monoclonal antibody. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found on certain cells in the body. Pembrolizumab has been designed to attach to and block an antigen called ‘programmed cell death-1’ (PD-1), which switches off the activity of certain cells of the immune system (the body’s natural defences) called T cells. By blocking PD-1, pembrolizumab prevents PD-1 from switching off these immune cells. This increases the ability of the immune system to kill tumour cells. It has already been approved for the treatment of NSCLC).
Patients who are eligible to participate on this study will be assigned by chance (one chance in two) to one of two treatment groups via a process called randomization. Patients assigned to treatment group one will the Nivolumab and Relatimab. Patients assigned to treatment group two will not recieve Pembrolizumab. About 1.000 people will be in the study in total.
Patient Profile
Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where’s this trial being run?
Beacon Hospital, St James’s Hospital, and Tallaght University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | CA224-1093 (RELATIVITY 1093) |
|---|---|
| Number: | 24-106 |
| Full Title: | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (RELATIVITY1093) |
| Principal Investigator: | Prof Jarushka Naidoo |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Bristol-Myers Squibb |
| Recruitment Started: |
Global: Oct 2024 Ireland: |
| Global Recruitment Target: | 1000 |
|---|---|
| Ireland Recruitment Target: |